Sangamo BioSciences | SGMO - Ebit


Sangamo BioSciences reported $-72.22M in EBIT for its fiscal quarter ending in June of 2023.





Ebit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amgen USD 3.96B 464M Dec/2025
Bayer EUR 1.11B 1.51B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD 56.04M 63.94M Dec/2025
CSL USD 2.64B 116M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
J&J USD 6.62B 1.51B Mar/2026
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Novartis USD 4.06B 530M Dec/2025
Omeros USD -48.15M 7.25M Sep/2023
Pfizer USD 4.65B 71M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025